Second, the BA model expresses physiological levels of a knock-in BRAFV600E mutant driven by the endogenous Braf promoter, whereas the transgenic model relies on the overexpression of a human BRAFV600K transgene, which attains expression of MAPK-target genes akin to levels in more advanced dysplastic tumours. Here, BRAF is linked to neoplasm.